Healthcare / Medical Instruments & SuppliesShanghai
$18.16
-0.40 (-2.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $100.8M · quality 75.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.0B
P/E
69.8x
↑EV/EBITDA
21.9x
↑ROE
3.1%
↑Gross Margin
27.9%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.2%
FCF CAGR
+8.8%
FCF margin
12.5%
FCF / Net income
2.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.14B · net income $51.5M · FCF $142.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.14B | $1.14B | $1.12B | $975.1M | $1.47B |
| Net Income | $51.5M | $51.5M | $171.6M | $109.1M | $326.0M |
| EBITDA | $168.7M | $168.7M | $285.2M | $204.7M | $411.9M |
| EPS | 0.23 | 0.23 | 0.78 | 0.49 | 1.48 |
| Gross Margin | 27.9% | 27.9% | 32.8% | 32.7% | 39.5% |
| Operating Margin | 10.0% | 10.0% | 14.5% | 11.9% | 23.1% |
| Net Margin | 4.5% | 4.5% | 15.4% | 11.2% | 22.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.03 | 0.02 | 0.00 |
| Current Ratio | 2.73 | 2.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $142.4M | $142.4M | $100.8M | $63.6M | $110.6M |
| Returns | |||||
| ROE | 3.1% | 3.1% | 10.1% | 6.7% | 20.5% |
| Valuation | |||||
| P/E | 69.85 | 69.85 | 24.84 | 52.39 | 37.94 |
| EV/EBITDA | 21.92 | 21.92 | 14.06 | 25.92 | 28.20 |
| P/B | 2.41 | 2.41 | 2.50 | 3.49 | 7.77 |
| Growth & Yield | |||||
| Revenue Growth | 1.8% | 1.8% | 14.4% | -33.6% | — |
| EPS Growth | -70.5% | -70.5% | 58.3% | -66.8% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
91.3%
EPS terminal req.
$1.61
Spread vs growth
-161.9%
5Y implied EPS CAGR
53.3%
EPS terminal req.
$1.95
Spread vs growth
-123.9%
10Y implied EPS CAGR
29.9%
EPS terminal req.
$3.14
Spread vs growth
-100.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.2%
Start / end P/E
28.4x → 79.0x
EPS bridge
0.78 → 0.23
Residual
-125.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.